Currently, the 10-mg dose of tofacitinib is only approved in the dosing regimen for patients with ulcerative colitis. When tofacitinib received FDA approval, the agency called for a clinical trial among RA patients to evaluate the risk for heart-related events, cancer, and infections with tofacitinib doses of 5 mg and 10 mg twice daily combined...